Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Condition:   Metastatic Breast Cancer Intervention:   Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor:   Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials